Therapeuticsmd, Inc.

Sancilio & Company, Inc.

Micelle Biopharma, Inc.

Vtv Therapeutics LLC

Generx, Inc.

Thorsteinn Thorsteinsson

Frederick D Sancilio

Julia M Amadio

Peter H R Persicaner

Brian A Bernick

Janice Louise Cacace

Neda Irani

Annette M Shadiack

Eric Joel Benjamin

Jason D Legassie

Philip B Inskeep

Ahmed Abd Almalik Ahmed Mohammed Daak

Miguel Lopez-Toledano

Glynis Daniel-Archibald

Richard Winneker

Ajay Ghanta

Veeran Gowda Kadajji

Mafruhul Bari

Siva Kumar Rapuru

Peter H Persicaner

Ahmed Abd Daak

Eric Benjamin

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Progesterone formulations having a desirable PK profile

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.

Steroid hormone pharmaceutical formulations

According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Soluble estradiol capsule for vaginal insertion

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Vaginal inserted estradiol pharmaceutical compositions and methods

Progesterone formulations having a desirable pk profile

Compositions and methods for the solubilization of steroid hormones are disclosed.

Formulations for solubilizing hormones

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Sickle cell disease treatment utilizing omega-3 fatty acids

Mold for a medical dosage form

Growing community of inventors

Boynton Beach, FL, United States of America

Thorsteinn Thorsteinsson